Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance after tandem autologous-allogeneic transplant in newly diagnosed multiple myeloma
2008-004529-41Phase 2Terminated
- Sponsor
- Fondazione EMN Italy
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoints: Toxicity and tolerability of lenalidomide after allografting and Complete remission at 12 months after allografting. Started Nov 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-004529-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004529-41.